Thymalin

Overview

Thymalin is a polypeptide complex extracted from calf (young bovine) thymus, developed by V.G. Morozov and V.Kh. Khavinson in Leningrad/St. Petersburg during the 1970s (Military Medical Academy / Institute of Bioregulation and Gerontology), and registered as a pharmaceutical drug in the USSR/Russia since 1982 (manufactured by Samson-Med). Thymalin is a heterogeneous mixture of short peptides ranging from 2-8 amino acids, with an overall molecular weight range of roughly 1,000-10,000 Da — it is not a single defined compound. Identified active fragments include the EW dipeptide (Glu-Trp, marketed separately as Thymogen), the KE dipeptide (Lys-Glu, marketed as Vilon), and the EDP tripeptide (Glu-Asp-Pro, marketed as Crystagen). As a thymic bioregulator, it accelerates T-lymphocyte maturation, restores the B/T lymphocyte ratio, and modulates pro-inflammatory cytokines. In Russia it is used clinically for immunodeficiency, immune recovery after chemo/radiotherapy, bronchial asthma, and disorders of tissue repair. Nearly all clinical evidence originates from the Khavinson research group, and no independent Western replication studies have been published. Vialdyne releases Thymalin as a lyophilized two distinct identities under one sku: thymalin is a heterogeneous peptide/protein extract mixture (no single molecular type applies); thymulin (fts) is a defined nonapeptide (linear, zinc-binding-dependent activity) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.

Applications & buyer fit

Buyers in this category are research labs studying immune-modulation, cytokine signaling, and antimicrobial activity. The defining QC requirement is bacterial-endotoxin control: many of the downstream assays (NF-κB reporters, macrophage activation panels, neutrophil-priming readouts) are themselves activated by endotoxin contamination, so a clean LAL on the specific batch is a precondition rather than a nice-to-have. LL-37 and related cationic antimicrobial peptides additionally benefit from low-bind plasticware during dilution.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

79621-14-0

Molecular Weight

1000 g/mol

Sequence

Multi-component peptide mixture (no single sequence)

Appearance

White lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30 minute

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Thymalin; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Thymalin/Thymulin

VD260428-THY10203 · 99.33%

Independent analytical testing

Product- and strength-matched first-page previews are shown separately from Vialdyne's lot-specific Batch COAs. Reference the report number when requesting the complete, high-resolution file from sales.

Third-party testView report record →

Thymalin

10 mg · HPLC / MS

TY10-20260806S9397

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):233-40.
2. Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews. 2021;11(4):377-382. doi:10.1134/S2079086421040046
3. Kuznik BI, Khavinson VK, Shapovalov KG, Linkova NS, Lukyanov SA, Smolyakov YuN, Tereshkov PP, Shapovalov YuA, Konnov VA, Tsybikov NN. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology. 2021;11(4):368-376. doi:10.1134/S2079057021040068
4. Linkova NS, Khavinson VKh, Diatlova AS, Petukhov MG, Vladimirova EA, Sukhareva MV, Ilina AR. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023;24(17):13377. doi:10.3390/ijms241713377
5. Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020;170(1):118-122. doi:10.1007/s10517-020-05016-z
6. Zhukova GV, Schikhlyarova AI, Barteneva TA, Shevchenko AN, Zakharyuta FM. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med. 2018;165(1):80-83. doi:10.1007/s10517-018-4104-z

Frequently asked questions